Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 5/20 | 0.42 |
| ▸ | AR | P10275 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5566469 | 0.88 | VDR (0.51) | VDRARSMN1; SMN2MAPK1HPGD | |
| SCHEMBL5568949 | 0.86 | VDR (0.43) | VDRARALDH1A1KDM4EHTT | |
| SCHEMBL5565295 | 0.82 | ALDH1A1 (0.41) | ALDH1A1KDM4EHTTSMN1; SMN2MAPK1 | |
| SCHEMBL5569389 | 0.77 | BACE1 (0.51) | ALDH1A1KDM4EPPARGPPARAGAA | |
| SCHEMBL6257981 | 0.74 | MRGPRX4 (0.39) | VDRARALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL27734485 | 0.74 | VDR (0.35) | VDRARALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL5569801 | 0.74 | VDR (0.53) | VDRARHTTPPARGPPARA | |
| SCHEMBL28755289 | 0.73 | KMT2A (0.36) | VDRARALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL28773091 | 0.72 | PPARA (0.58) | ALDH1A1KDM4EPPARGPPARAGAA | |
| SCHEMBL13332007 | 0.72 | ALDH1A1 (0.56) | ALDH1A1KDM4EHTTSMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312249-B2 | Vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-12-25 | — | — | US | disclosed |
| EP-1537065-B1 | ANALOGUES OF VITAMIN D | GALDERMA RES & DEV (FR) | 2006-11-02 | — | — | EP | disclosed |
| US-20050182144-A1 | Novel vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182144-A1 | Novel vitamin D analogues | CYP24A1, CYP2R1, VDR | VDR 3/4885AR 476/4885ALDH1A1 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.